The Latest Breaking News from BMY

Amid rising global medical needs, the pharmaceutical industry is expected to witness robust growth in the coming years. Moreover, healthcare is considered relatively resilient amid market downturns. So, given the economic uncertainties, investors could consider buying quality pharmaceutical stocks such as Pfizer (PFE), Novartis (NVS), and Bristol-Myers Squibb (BMY) this…

While the moderate inflation rate for November has boosted investor sentiment and may have paved the way for lower interest rate hikes from this month, Fed’s recent comments suggest that the target interest rate may be a bit further ahead. Hence shares of fundamentally strong businesses with robust demand, such…

Although inflation is still sky-high, and the Fed’s rate hikes are expected to continue, experts believe the economy might succeed in avoiding a recession. Given the uncertainties, we think investors should load up on fundamentally sound stocks Bristol-Myers Squibb (BMY), Waste Management (WM), and Hillenbrand (HI) as we head into…

Pharma company Bristol-Myers Squibb (BMY) is working on strengthening its pipeline and has raised its annual dividend recently. Hence, the stock might be a solid addition to your portfolio this month. Read on….

While the stock market has been under pressure this year, medical stocks have remained resilient due to the inelastic demand for their offerings. Moreover, the demand for medical goods and services is rising amid increasing health awareness and chronic diseases. Given the solid prospects of the industry, fundamentally sound medical…

The Fed indicated a slowdown in its rate hike pace ahead, boosting investors' optimism. Moreover, the economy is showing resilience in the face of macro headwinds. As December is known to be a strong month for the stock market, investors could load up on fundamentally solid stocks, Microsoft (MSFT), Bristol-Myers…

Despite economic uncertainties, leading pharma company Bristol-Myers Squibb (BMY) beat street estimates in the fiscal third quarter with solid financials. However, given the current market turmoil, is it too late to get on the upward move in this stock? Continue reading to find out.

The Fed Chairman recently indicated a slower pace of rate increases. However, many analysts still believe the economy will face a mild recession next year. Therefore, it could be wise to invest in quality stocks with solid growth prospects, such as AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Lifeway Foods (LWAY).…

Consumer confidence dropped month-over-month in November. However, it remains well above the mark, indicating a healthy economy. We think investors’ quality stocks, UnitedHealth Group (UNH) and Bristol-Myers Squibb (BMY), which have solid dividend-paying records, could help navigate the uncertainties. However, fundamentally weak Peloton Interactive (PTON) and Mullen Automotive (MULN) might…

The Fed is likely to slow down its aggressive monetary policy as analysts believe the economy is finally losing momentum and inflation should decline in the next year. Therefore, investors should consider adding fundamentally sound stocks Bristol-Myers (BMY) and ARC Document (ARC) to their portfolios to ensure a stable passive…

Although the stock market has seen a decline in inflation for October, it is far from the Fed’s target, and rate hikes might continue. However, the anticipation of a strong stock market rebound in 2023 is rising. So, we think it could be wise to load up on fundamentally sound…